Crinetics Pharmaceuticals (CRNX) Receivables - Net (2017 - 2026)
Crinetics Pharmaceuticals' (CRNX) quarterly Receivables - Net came in at $5.7 million in Q1 2026, up 859.97% quarter-over-quarter from $592000.0 in Q4 2025.
Crinetics Pharmaceuticals (CRNX) Receivables - Net (2017 - 2026) Analysis & Trends
Crinetics Pharmaceuticals' Receivables - Net history runs 5 years deep, the most recent figure standing at $5.7 million for Q1 2026.
- On a quarterly basis, Receivables - Net changed N/A year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $592000.0, changed N/A from the prior year.
- Receivables - Net climbed to $5.7 million in Q1 2026 per CRNX's latest filing, from $592000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $5.7 million in Q1 2026 and bottomed at $592000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Crinetics Pharmaceuticals | 8.71 Bn | 8.71 Bn | 10.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.68 Mn |
| Mar 31, 2026 | 5.68 Mn |
| Dec 31, 2025 | 592,000.00 |
| Dec 31, 2025 | 592,000.00 |
| Dec 31, 2019 | 225,000.00 |
| Dec 31, 2019 | 225,000.00 |
| Sep 30, 2019 | 205,000.00 |
| Sep 30, 2019 | 205,000.00 |
| Mar 31, 2019 | 415,000.00 |
| Mar 31, 2019 | 415,000.00 |
| Dec 31, 2018 | 568,000.00 |
| Dec 31, 2018 | 568,000.00 |
| Sep 30, 2018 | 510,000.00 |
| Sep 30, 2018 | 510,000.00 |
| Jun 30, 2018 | 657,000.00 |
| Jun 30, 2018 | 657,000.00 |
| Dec 31, 2017 | 231,000.00 |
| Dec 31, 2017 | 231,000.00 |